Haemorrhagic cystitis (HC) is the syndrome of haematuria and symptoms of lower urinary tract irritability in the absence of bacterial infection. We report a low incidence of HC (18.2%) in 681 haemopoietic stem cell transplant patients, using a prophylactic regimen of hyperhydration and forced diuresis. The incidence of grade 3-4 disease is 3.4%. There was a marked difference in incidence between allogeneic and autologous transplant populations, 24.2% vs 3.5% (P Ͻ 0.0005). Busulphan conditioning, acute GVHD, interstitial pneumonitis and use of methotrexate and cyclosporin immune suppression were associated with significantly increased incidence of HC in the allogeneic population. This may reflect the numerous factors that contribute to the greater immunosuppression and consequent increased risk for HC in allogeneic transplantation.
Haemorrhagic cystitis (HC) is the syndrome of haematuria and symptoms of lower urinary tract irritability in the absence of bacterial infection. It is responsible for significant morbidity after haemopoietic stem cell transplantation (HSCT). Cyclophosphamide toxicity has been thought to be the main factor in its pathogenesis. The acrolein formed as a urinary byproduct of the metabolism of cyclophosphamide is thought to be responsible for urothelial toxicity, with the bladder most at risk due to prolonged exposure. 1, 2 Uro-protective measures include: hyperhydration; induced diuresis; frequent voiding; bladder irrigation and administration of 2-mercaptoethane sodium (Mesna). Mesna is believed to act by binding to acrolein creating an inert thioether which passes innocuously in the urine. 3 To date, only one of many prospective randomised studies showed an advantage of Mesna over hyperhydration in uroprotection. 4 Other studies showed no difference in efficacy. [5] [6] [7] Despite this, Mesna is increasingly adopted as a standard of care in patients receiving HSCT. This, and an increasing incidence of HC among our patients, prompted us to review our protocol of hyperhydration and induced diuresis in a large allogeneic and autologous haemopoietic stem cell transplant population. We assessed both the incidence and severity of HC. We also sought to identify other factors associated with increased incidence of HC.
Patients and methods
The study population consisted of patients undergoing first allogeneic bone marrow or stem cell transplantation at St Vincent's Hospital, Sydney between March 1981 and December 1997 and those undergoing autologous bone marrow or stem cell transplantation for malignancy between June 1987 and December 1997. All transplant patients at St Vincent's are monitored daily while in hospital and periodically via correspondence and clinic visits after discharge. Details of clinically significant adverse events including type, severity and duration are registered and coded in consultation with clinicians in twice weekly meetings.
HC was defined as the presence of microscopic or macroscopic haematuria in the presence of symptoms of lower urinary tract irritability. Bacterial infection was excluded by negative culture. Severity of HC was not coded in the registry records and was graded retrospectively on review of each patient's medical record. The grade of HC was based on a system proposed by Droller et al 8 as follows: grade 1, microscopic haematuria; grade 2, macroscopic haematuria; grade 3, macroscopic haematuria with clots; grade 4, severe haematuria requiring instrumentation for clot evacuation and/or causing urinary tract obstruction.
For all in-patients urine samples were monitored daily for the presence of blood. Positive dipstick tests were followed by urine microscopy and bacterial culture. Viral cultures were not performed. Eighteen patients with haematuria in the absence of irritative symptoms were excluded from study. Early onset HC was defined as that occurring from day −7 to day +7, and late onset disease from day 8 onwards.
A total of 681 individuals were included in the study. Four hundred and eighty-three patients received allogeneic and 198 autologous transplants. All patients received cytoreductive chemotherapy. A number of conditioning regimens were used (Table 1 ) but the two most frequent in the allogeneic population were cyclophosphamide (60 mg/ kg × 2 doses), and total body irradiation in 268 patients; and busulphan (4 mg/kg × 4 doses), and cyclophosphamide in 183 patients. All but one patient in the allogeneic population received cyclophosphamide in the conditioning regi- 
Statistical analysis
Kaplan-Meier projection was used to calculate the incidence of HC. Clinical risk factors including sex, age, underlying diagnosis, conditioning regimen, CMV status and prophylaxis, year of transplant and acute GVHD were analysed for their effect on the development of HC. Differences were compared in univariate analysis. To correct for the effect of confounding variables, multivariate analysis was also performed. 9 The procedure used was a logistic regression with the incidence of HC as dependent variable and the following independent variables; age (continuous); gender (1 = male, 0 = female); GVHD prophylaxis (methotrexate plus cyclosporin = 1, 0 = other); time of transplant (1990-1997 = 1, 0 = prior to 1990); GVHD incidence (grade II or higher = 1, 0 = other); pretransplant conditioning (busulphan in conditioning = 1, 0 = other); interstitial pneumonitis (1 = yes, 0 = no). Kaplan-Meier survival curves were constructed for patients who had HC compared to those who did not. 
Results
A total of 124 of 681 patients experienced HC giving an overall incidence of 18.2% in our transplant population. Grade 3 or 4 disease occurred in 23 patients (3.4%). Grade 4 disease occurred in nine patients (1.3%). Early onset disease occurred in 47 (6.9%). Median day of onset was day 19 post transplant. There was a marked difference in incidence in the allogeneic compared to the autologous transplant population, 24.2% vs 3.5% (P Ͻ 0.0005), and so further analysis was done separately for each population.
Allogeneic transplants
Of 483 allogeneic transplant recipients, 117 (24.2%) developed HC between day −7 and day +180 post transplant. Figure 1 shows two distinct populations with 45 episodes (38.4%) occurring in the first 2 weeks after commencing conditioning (ie up to day 7 post transplant), and 72 cases (61.6%) occurring thereafter. Severity of disease was as follows: grade 1, 42 patients (36.5%); grade 2, 52 patients (44.4%); grade 3, 14 patients (12.0%); and grade 4, nine patients (7.7%). Median duration of HC was 14 days for those with grade 1-2 disease and 37 days for those with grade 3-4 disease. There was a significant difference in the median duration of HC according to time of onset, with those patients having early onset grade 3-4 disease having a median duration of 90 days, compared to 16 days for those who had grade 3-4 HC onset beyond day 7 post transplant (P = 0.001). However, there was no significant difference in severity between early and late onset HC (P = 0.78). The median duration of first hospitalisation was not significantly different for those who did not experience HC (25 days) and those who had grade 1-2 disease (26 days) or grade 3-4 disease (27 days). Likewise, duration of transplant admission was no longer for those with early onset disease compared to those with late onset HC, 25 days cf. 26 days.
Risk factors for HC, univariate analysis:
Six factors were significantly associated with increased incidence of HC in allogeneic transplants (Table 3) . Use of busulphan in the conditioning regimen resulted in an incidence of 39.3% compared to 15.0% ( 2 = 49.3, P Ͻ 0.0005). However, the association between busulphan and HC is not stronger for those with early onset disease. There was a doubling of incidence of HC in the 1990s compared to the 1980s: 33.8 vs 15.9%, ( 2 = 33.5, P Ͻ 0.0005). The incidence was higher for patients who received methotrexate and cyclosporin as graft-versus-host disease (GVHD) prophylaxis: 35.3% compared with 13.5%, ( 2 = 43.9, P Ͻ 0.0005). Those receiving methotrexate/cyclosporin had significantly more late onset HC (20.6%), compared with an incidence of early onset disease of 9.4% ( 2 = 11.9, P = 0.001). The incidence was also higher in patients who experienced acute GVHD of grade II or higher severity, 31.2% compared with 21.8% ( 2 = 6.1, P = 0.01). Patients experiencing interstitial pneumonitis also had a higher incidence of HC, 38.8% compared to 21.3% ( 2 = 11.9, P Ͻ 0.001). There was a significantly increased incidence in those using ganciclovir prophylaxis compared to no prophylaxis ( 2 = 28.4, P = 0.0005). A trend to a higher incidence was noted in those with a pretransplant diagnosis of chronic myeloid leukaemia 30.6% compared with 21.1% in patients with other diagnoses ( 2 = 3.4, P = 0.07). There was no significant difference in incidence between those receiving matched sibling transplants, compared to matched unrelated and mismatched related transplants (P = 0.7). This may reflect the small number of mismatched and unrelated transplants.
Risk factors for HC, multivariate analysis:
Multivariate analysis using logistic regression showed that busulphan conditioning, methotrexate plus cyclosporin use, interstitial pneumonitis and acute GVHD grade II or greater were associated with increased incidence. Age, gender, diagnosis, year of transplant, CMV status and use of CMV prophylaxis were not significant predictors of increased incidence. The regression was then re-run omitting the nonsignificant variables (Table 4) .
One patient died from unremitting HC. However, Kaplan-Meier survival curves show no difference in overall survival between patients who did and did not have HC (P = 0.256) (Figure 2 ).
Autologous transplants
A total of seven of 198 autologous transplant recipients developed HC, an incidence of 3.5% (Table 5 ). All seven patients belonged to the group of 163 patients who received cyclophosphamide. Severity was graded as follows: grade 1, two patients, grade 2, four patients, grade 3, one patient, grade 4, no patients. While the incidence of HC was higher for those patients whose conditioning included cyclophos- phamide: 4.3% compared to 0.0% ( 2 = 1.6, P = 0.2), because only 35 patients did not receive cyclophosphamide statistical significance was not obtained. The incidence of HC was significantly higher for patients whose conditioning included busulphan, 8.5% compared to 1.4% ( 2 = 6.0, P = 0.01). Further regression model analysis was prevented by the small number of autologous transplants and the low incidence of HC in this population.
Discussion
HC is a transplant complication responsible for significant morbidity and cost. The primary purpose of this study was to assess its incidence and severity in a HSCT population who did not receive Mesna prophylaxis. This was not a prospective randomised trial and comparisons with other studies are hampered by small study sizes, and differing disease definitions and study populations. However, our overall incidence of 18.2% compares favourably with most other studies which report incidences ranging from 15 to 76%.
5,7,10-14 Our 3.4% incidence of grade 3-4 disease is low compared to a range of 5.5% 8 to 20.8% 11 reported previously. The higher proportion of patients with low grade disease in our study may reflect a wider definition, creating a higher incidence. We included any documented haematuria, no matter how transient, provided patients had symptoms of bladder irritability. In comparison, the largest reported study of 977 patients excluded those with transient microhaematuria. In this study patients received Mesna, with an incidence of HC of 15%. 10 Previous studies of HC have identified cyclophosphamide as an important aetiologic agent.
1,2 Almost all our patients received cyclophosphamide in their conditioning. The absence of significant numbers not receiving cyclophosphamide prevents us from identifying cyclophosphamide as a risk factor. The role of cyclophosphamide may be reflected in our finding of significantly longer lasting disease in those with early onset HC.
The significantly different incidence between our allogeneic and autologous populations, 24.2% compared with 3.5%, indicates that HC is predominantly an allogeneic disease. It is difficult to explain the very low incidence in the autologous population, most of whom also received cyclophosphamide. The accompanying greater immune suppression of allogeneic transplantation may potentiate a multifactorial pathogenesis of HC. We have identified an increased incidence in patients with several immunosuppressive factors. Busulphan conditioning is significantly associated with increased incidence and the doubling of incidence in the 1990s reflects the increased use of busulphan. The introduction of methotrexate and cyclosporin immunosuppression in the early 1990s, also contributed to the increased incidence of HC.
There is increasing support in the literature for the cytopathic effect of BK virus on uroepithelial cells being important in the aetiology of late onset HC. 7, 11, 15 The immune suppression associated with methotrexate and cyclosporin may well be a factor in HC related to reactivation of BK virus, as our patients on methotrexate/cyclosporin had a significantly greater incidence of late onset HC. The presence of grade II or greater severity of acute GVHD is a significant risk factor for HC and probably also reflects both an allogeneic and immunosuppressive effect of GVHD. The increased incidence in patients with interstitial pneumonitis is of uncertain significance. This may reflect a drug, or once again, an allogeneic effect. It may be a manifestation of GVHD of the lung interstitium.
Our transplant population has the lowest reported incidence of severe HC. Although associated with severe morbidity in 1.9% of our allogeneic population and the cause of death for one patient, HC did not increase duration of transplant admission nor overall mortality, and in 81% of cases it was a mild self-limiting disease. Although Mesna use is widespread, our study reassures us that our hyperhydration-forced diuresis protocol is at least as effective in preventing HC and we are continuing with this regimen. However, whether Mesna administration in addition to hyperhydration and forced diuresis is superior prophylaxis to either method alone remains to be determined.
The higher incidence in allogeneic transplants and the associated immunosuppressive risk factors of busulphan conditioning, acute GVHD, interstitial pneumonitis and use of methotrexate and cyclosporin immunosuppression are reflected by an increased incidence of HC in the 1990s. This supports the hypothesis of a multifactorial pathogenesis of HC. Further investigation into the contributory roles of these risk factors and possible cytopathic effect of BK viruria is indicated.
